Stephen S. Burkhart, M. D. and Burkhart Resource Limited Partnership v. Arthrex, Inc.
CourtDistrict Court of Appeal of Florida
Date FiledJuly 1, 2022
Docket2D21-2223
StatusPublished
📰 News Coverage: Read the LAWS.com news report on this case
Full Opinion
DISTRICT COURT OF APPEAL OF FLORIDA
SECOND DISTRICT
STEPHEN S. BURKHART, M.D., and BURKHART RESOURCE
LIMITED PARTNERSHIP,
Appellants,
v.
ARTHREX, INC.,
Appellee.
No. 2D21-2223
July 1, 2022
Appeal pursuant to Fla. R. App. P. 9.130 from the Circuit Court for
Collier County; Hugh D. Hayes, Judge.
Marie A. Borland and Dennis P. Waggoner of Hill, Ward &
Henderson, P.A., Tampa; Chris W. Altenbernd of Banker Lopez
Gassler P.A., Tampa; and John C. O'Quinn of Kirkland & Ellis LLP,
Washington, District of Columbia, for Appellants.
Marshall P. Bender and Jason Hunter Korn of Dentons Cohen &
Grigsby P.C., Naples; and Douglas L. Sawyer, Geoffrey A. Vance,
and Mark T. Smith of Perkins Coie LLP, Chicago, Illinois, for
Appellee.
ATKINSON, Judge.
Inventor Stephen S. Burkhart, M.D., and his entity, Burkhart
Resource Limited Partnership (collectively, Dr. Burkhart), sued
medical device company Arthrex, Inc., alleging that Arthrex
breached the parties' 2008 royalty agreement by failing to pay the
amounts due to him under the agreement. Arthrex filed a
counterclaim asserting that Dr. Burkhart breached the parties'
2013 royalty agreement based upon what it alleged to be Dr.
Burkhart's misrepresentation that the assigned patents did not
infringe on the intellectual property rights of any third parties and
his failure to indemnify Arthrex from the losses it suffered as a
result of third-party patent-infringement claims.
Dr. Burkhart appeals from the order entered by the trial court
that disqualified his counsel, directed the return of certain
communications produced in response to Arthrex's request for
production, and barred Dr. Burkhart from utilizing those
communications during the litigation. Because these
communications are not covered by the attorney-client privilege, we
reverse the trial court's order.
2
I. Background
In 2008, Arthrex and Dr. Burkhart entered into a royalty
agreement. Under the agreement, Dr. Burkhart assigned all rights,
title, and interest in certain identified products, as well as
enhancements to those products, in exchange for a quarterly
royalty payment. And Arthrex was responsible for the preparation
of all applications for these "royalty bearing products." The royalty
agreement also contained a mutual confidentiality provision
whereby they agreed to "maintain in strict confidence all
Confidential Information and not disclose it to any third party" and
to "use, at a minimum, reasonable care to protect the Confidential
Information." They further agreed "not [to] use any Confidential
Information except as permitted by this Agreement or may be
necessary to perform obligations under this Agreement."
After the parties' efforts to amicably resolve the disputes failed,
Dr. Burkhart filed suit against Arthrex. During the course of
discovery, Arthrex requested that Dr. Burkhart produce, among
other things, "[a]ll communications exchanged between [Dr.
Burkhart] and Arthrex during the period 2008 to the present" as
3
well as "[a]ll documents which refer, regard, reflect or relate to Dr.
Burkhart's disclosure of inventions or designs to Arthrex."
In response, Dr. Burkhart, through his trial attorneys,
produced responsive documents in his possession, including
communications exchanged between Dr. Burkhart and counsel for
Arthrex over the course of years. Arthrex initially identified thirty
documents as privileged. After Dr. Burkhart moved the court to
rule on those objections, Arthrex filed a motion in which it identified
as privileged an additional 161 documents. In that motion, Arthrex
sought to preclude Burkhart from using those documents and to
disqualify Dr. Burkhart's attorneys who had reviewed those
documents. In a supplemental log, Arthrex subsequently claimed
that 1,576 documents were privileged.
Without conducting an in-camera inspection of the
documents, the trial court declared them privileged and barred Dr.
Burkhart from using the documents either in discovery or at trial.
It also disqualified Dr. Burkhart's trial counsel based upon the
firm's review and production of the "privileged" documents. Dr.
Burkhart appeals these rulings.
4
II. Jurisdiction
Orders that "grant or deny a motion to disqualify counsel" are
appealable nonfinal orders. See Fla. R. App. P. 9.130(a)(3)(E).
Because the disqualification ruling was dependent upon the trial
court's determination that the documents were privileged, we must
review that finding as part of our review of the nonfinal order of
disqualification over which we have interlocutory jurisdiction.
However, the portion of the order that precludes Dr. Burkhart from
using the documents in discovery or at trial is not appealable. See
Wyndham Vacation Resorts, Inc. v. Timeshares Direct, Inc., 123 So.
3d 1149, 1151 n.4 (Fla. 5th DCA 2012) ("[W]e do not have
jurisdiction to review by non-final appeal, that part of the summary
final judgment that dismissed Wyndham's claim for FDUTPA
damages. The procedural limitations imposed by the rules do not
permit review of 'tag along' orders contained within reviewable non-
final orders." (citation omitted)); Consultants & Designers v. Brown,
677 So. 2d 915, 917 (Fla. 1st DCA 1996) ("[C]ourts have repeatedly
rejected the contention that they possess jurisdiction to review
rulings on other issues merely because they are included in an
order that rules on one of the specific issues listed in rule
5
9.130(3)."). Rulings "not enumerated in [r]ule 9.130 must await
review at the end of the case, unless they meet the standard for
certiorari or another extraordinary writ." RD & G Leasing, Inc. v.
Stebnicki, 626 So. 2d 1002, 1003 (Fla. 3d DCA 1993). The portion
of the order that merely denies discovery is not reviewable by
certiorari because there is no irreparable injury. See Katz v.
Riemer, 305 So. 3d 663, 666 (Fla. 3d DCA 2020) ("Irreparable injury
can rarely be shown where discovery is denied, as any error is
generally reviewable on appeal."); see also State Farm Mut. Auto. Ins.
v. Peters, 611 So. 2d 597, 598 (Fla. 2d DCA 1993) ("Ordinarily,
certiorari is not available to review an interlocutory order denying
discovery because the harm from such orders can be rectified on
appeal." (citing Esman v. Bd. of Regents, 425 So. 2d 156, 157 (Fla.
1st DCA 1983))); Riano v. Heritage Corp. of S. Fla., 665 So. 2d 1142,
1144 (Fla. 3d DCA 1996) ("In the rare cases where certiorari is
granted, the petitioner has met the heavy burden of demonstrating
irreparable injury by showing that without an order compelling
discovery, information critical to the case would never be known
and would not be available to the appellate court for review."). And
the portion of the order that precludes Dr. Burkhart from utilizing
6
the "privileged" documents at trial is, as would be a motion in
limine, similarly unreviewable. See Patterson v. Whitehead, 360 So.
2d 1136, 1136 (Fla. 1st DCA 1978) ("Though prospective evidentiary
rulings are often convenient and desirable, they may not ordinarily
be reviewed immediately by proceedings in the nature of common
law certiorari.").
III. Privilege and Disqualification
As a basis for its motion to disqualify opposing counsel,
Arthrex sought to characterize Dr. Burkhart and his lawyers' use of
documented communications on which Dr. Burkhart was the
sender or the intentionally listed recipient as a violation of attorney-
client privilege. Dr. Burkhart had these communications in his
possession and produced them as responsive to discovery requests
propounded by Arthrex, who itself (or its counsel) was a listed
sender or recipient of the communications. The documents were
not protected by the attorney-client privilege under the
circumstances of this case, and there is no evidence to indicate that
Dr. Burkhart or his attorneys intended to—much less did—violate
attorney-client privilege. As such, the motion seeking and the order
7
imposing disqualification of Dr. Burkhart's counsel were bereft of
support.
Section 90.502, Florida Statutes (2021), governs the attorney-
client privilege and confers a privilege on a client "to refuse to
disclose, and to prevent any other person from disclosing, the
contents of confidential communications when such other person
learned of the communications because they were made in the
rendition of legal services to the client." See § 90.502(2). Those
"confidential communications" of which a client has a right to
prevent disclosure are defined as "communication[s] between lawyer
and client" that are "not intended to be disclosed to third persons."
§ 90.502(1)(c). Because Arthrex intended the communications to be
disclosed to Dr. Burkhart and his attorneys—third parties to the
relationship between Arthrex and its lawyers—the communications
are not "confidential communications" and are not protected by the
attorney-client privilege. Cf. Jenney v. Airdata Wiman, Inc., 846 So.
2d 664, 667 (Fla. 2d DCA 2003) (denying in part petition for
certiorari challenging order compelling production of documents in
an attorney's possession because they were not "confidential
communications").
8
Arthrex argues that communications with its attorneys in
which Dr. Burkhart was a participant satisfy the requirements for
attorney-client privilege, relying on language in the lawyer-client
privilege statute providing that a communication can still be
deemed confidential even if the communication was intended to be
disclosed to third parties "to whom disclosure is in furtherance of
the rendition of legal services to the client" and to "[t]hose
reasonably necessary for the transmission of the communication."
See § 90.502(1)(c). However, that provision does not apply to the
communications at issue because they were not disclosed to Dr.
Burkhart in furtherance of the rendering of legal services to
Arthrex; rather, Dr. Burkhart was a participant in the
communications as part of discussions between Arthrex and Dr.
Burkhart that also included the participation of their respective
legal counsel.
The documents deemed to be covered by Arthrex's attorney-
client privilege against disclosure by Dr. Burkhart were actually Dr.
Burkhart's documents—they were not Arthrex's private
conversations with its lawyers that had been "disclos[ed]" to Dr.
Burkhart or that he had "learned of," see § 90.502(1), (2), or to
9
which Dr. Burkhart had been made privy only as an employee or
consultant in order to effectuate the provision of legal services to
Arthrex. Of all the documents over which Arthrex successfully
sought to extend its attorney-client privilege, Dr. Burkhart had
either authored the communication and sent it to Arthrex or
Arthrex (or its counsel) had authored the communication and sent
it to Dr. Burkhart (and sometimes to Dr. Burkhart's counsel). This
characterization is confirmed by Arthrex's own description of the
documents in their answer brief, in which it avers that "[e]very
document at issue involves an Arthrex lawyer and Dr. Burkhart, as
an inventor, communicating to support Arthrex’s undisputed 'sole
and exclusive' right to prosecute patent applications." And the
language of Arthrex's pertinent discovery requests—to which these
communications were responsive—underscores that Dr. Burkhart
had come into rightful possession of all of these documents because
he either sent the communications or received them from Arthrex:
"All communications exchanged between you [Dr. Burkhart] and
Arthrex . . . ."; "All documents which refer, regard, reflect or relate to
Dr. Burkhart's disclosure of inventions or designs to Arthrex"; "All
documents which refer, regard or relate to any requests Dr.
10
Burkhart made to Arthrex to be added as a named inventor on a
patent or patent application, as well as any documents reflecting
any responses to those requests"; "All documents which refer,
regard, reflect or relate to any communications that any of the
Burkhart Parties sent to or received from [Arthrex's counsel] that
refers, regards or otherwise relates to Arthrex." (Emphasis added.)
In its answer brief, Arthrex recounts that it "found its
privileged documents in [Dr. Burkhart's] production." That is
because Dr. Burkhart was a part of all of the communications in
the first place. Arthrex sought—and the trial court granted—an
attorney-client privilege against Dr. Burkhart disclosing
communications he had made and communications Arthrex had
intentionally sent him. In other words, the communications were in
Dr. Burkhart's possession because Arthrex wanted him to have
them or they had originated from him.
This is not a typical scenario of an inadvertent disclosure to a
third party of an attorney-client communication to which that third
party should not have been privy—or should only have been privy
for a circumscribed purpose that served the attorney-client
relationship. Rather, Arthrex has advanced a novel application of
11
the attorney-client privilege to impose on a third-party recipient,
whose receipt of the communications was not inadvertent, the duty
to protect the sender's attorney-client communications that it
willingly conveyed to the recipient as part of a mutually beneficial
exchange of information related to an endeavor in which both the
sender and recipient were arms-length participants. But the fact
that the parties to that exchange of information sometimes included
their lawyers in the conversation does not transform the records of
the parties' discussions into attorney-client communications
enjoying a privilege that one participant can exert over the other.
Cf. Jenney, 846 So. 2d at 667 ("The fact that Jenney may have given
a copy of the employment agreement to the attorney negotiating the
retirement agreement does not convert the nonprivileged
employment agreement into a privileged document. Here, the
employment agreement was not privileged in Jenney's hands.
Therefore, it is not privileged in his former attorney's hands."
(citations omitted)).
These are not communications between an attorney and a
client that were inadvertently disclosed to a third party; these were
communications with a third party. They were not communications
12
between Arthrex and its attorney to which Dr. Burkhart might have
been privy either incidentally or accidentally, nor even by design on
the basis that disclosure to him was "reasonably necessary for the
transmission of the communication" or "in furtherance of the
rendition of legal services to" Arthrex. See § 90.502(1)(c); cf. Coulter
v. State Farm Mut. Auto. Ins., No. 4:12cv577-WS/CAS, 2013 WL
12102888, at *3 (N.D. Fla. June 20, 2013) (concluding that
possession of attorney-client communications by third parties was
" 'reasonably necessary' to transmit [the] communications to or
from Plaintiff and her counsel . . . because 'after the accident
[Plaintiff] was unconscious, heavily medicated, undergoing various
surgeries or procedures, or otherwise incapable of making rational
decisions given her condition [and] did not have regular access to
email or a fax machine' ").
These were communications from Arthrex to Dr. Burkhart on
which Arthrex's counsel was copied; communications from Dr.
Burkhart to Arthrex on which Arthrex's counsel was copied; or
communications to and from Dr. Burkhart and Arthrex's counsel.
They were not "confidential" communications that were "not
intended to be disclosed to third persons." See § 90.502(1)(c).
13
These were conversations between Arthrex and its lawyers and Dr.
Burkhart and his lawyers. And these were not "communication[s]
between lawyer and client" intended only "to be disclosed to third
persons . . . to whom disclosure is in furtherance of the rendition of
legal services to the client." See § 90.502(1)(c). Rather, these were
communications among a group of individuals that included Dr.
Burkhart and Arthrex and their respective attorneys. Dr. Burkhart
does not fall into the category of "[t]hose to whom disclosure is in
furtherance of the rendition of legal services to the client," see §
90.502(1)(c)1, because Arthrex did not disclose the communications
to Dr. Burkhart at all; rather, Dr. Burkhart was a part of the
communications from the time of their creation.
Arthrex contends that the relationship between Dr. Burkhart
and Arthrex was tantamount to an employer-employee relationship,
citing in support Shell Oil Co. v. Par Four Partnership, 638 So. 2d
1050, 1050–51 (Fla. 5th DCA 1994), and Hershey Co. v. Cadiz, No.
05-60999, 2006 WL 8431510 (S.D. Fla. Aug. 24, 2006). But
reliance on Shell Oil, Hershey, and similar cases is misplaced
because Dr. Burkhart's relationship with Arthrex is not that of an
employee or a consultant or any type of agent. Cf., e.g., United
14
States v. Advanced Pain Mgmt. & Spine Specialists of Cape Coral &
Fort Myers, No. 2:17-cv-272-FtM-29MRM, 2018 WL 4381192, at *9
(M.D. Fla. June 28, 2018) (explaining circumstances under which
an independent contractor may "be considered the functional
equivalent of an employee"). He is a collaborator with Arthrex in
their mutual endeavor to patent, produce, and sell medical devices
pursuant to a written, arms-length agreement. Indeed, the
agreement itself belies any notion that there was an employer-
employee or principal-agent relationship between Arthrex and Dr.
Burkhart: "Nothing in this Agreement will be construed to create a
partnership, joint venture, principal-agent, or employer-employee
relationship, and nothing herein will be deemed to authorize any
person to act for, represent, or bind any party except as specifically
set out herein."
Arthrex's reliance on the confidentiality agreement to establish
that the communications were attorney-client privileged further
reveals the frailty of its privilege argument. Such reliance tends to
undermine the existence of attorney-client privilege because the
confidentiality agreement presumes that Dr. Burkhart has an equal
interest in the confidentiality of the information and the prohibited
15
disclosure is to third parties—not each respective party's legal
counsel. The confidentiality provision might very well protect the
communications at issue in this appeal from disclosure to strangers
to the royalty agreement, but it does not prevent the parties to that
agreement from sharing them with their own attorneys.
Yet, Arthrex argues that the communications with its lawyers
to which Dr. Burkhart was privy were privileged in part because Dr.
Burkhart had entered into the confidentiality agreement. But the
confidentiality agreement was to protect information to which Dr.
Burkhart was privy against disclosure to third parties. See
Shvartser v. Lekser, 270 F. Supp. 3d 96, 98 (D.D.C. 2017) ("As a
general rule, 'confidentiality agreements will not stand as a barrier
to discovery between two parties in litigation.' " (quoting Saini v. Int'l
Game Tech., 434 F. Supp. 2d 913, 922 (D. Nev. 2006))); see also In
re Grand Jury Subpoena Dated Dec. 17, 1996, 148 F.3d 487, 492
(5th Cir. 1998) (" 'Confidential' does not necessarily mean
'privileged.' ").
The confidentiality agreement presumes that Dr. Burkhart and
Arthrex would be privy to the same information that they mutually
agreed to keep confidential from disclosure to others: "The parties
16
acknowledge that in connection with the performance of this
Agreement, each party will receive certain confidential or
proprietary technical and business information" and "[e]ach party
will . . . hold and maintain in strict confidence all Confidential
Information and not disclose it to any third party." Use of the
confidentiality provision to prevent Dr. Burkhart from divulging the
information to his own lawyer or from relying on it in litigation over
the very agreement that contains the provision defies common
sense—as does the notion that the confidentiality provision provides
support for the independent establishment of an attorney-client
privilege that only Arthrex can enjoy and which it could exert
against Dr. Burkhart.
Arthrex contends that "[w]hen [Dr. Burkhart's trial counsel]
received privileged communications between Arthrex’s patent
lawyers and Dr. Burkhart, they should have stopped reading the
documents, alerted Arthrex that Dr. Burkhart had given them
privileged material, and allowed Arthrex an opportunity to assert
and protect its privilege." Because the communications were not
privileged, it is not necessary to further explain why the attorneys'
failure to do so did not support their disqualification or to elaborate
17
on any of the other reasons why Arthrex's argument in favor of
opposing counsel's disqualification was meritless.
By this opinion, this court does not intend to suggest that no
arrangement between an inventor and a patent owner could ever
give rise to a privilege between the owner and its counsel that could
be exerted against the inventor's disclosure of attorney-client
communications. As it relates to the communications at issue in
this appeal, however, the parties' arrangement in this case did not
give rise to a privilege that could be asserted by Arthrex against Dr.
Burkhart in the manner that it attempted, much less one that
supports the disqualification of Dr. Burkhart's lawyers. Because
the trial court erred by disqualifying Dr. Burkhart's trial counsel,
we reverse.
Reversed and remanded.
VILLANTI and BLACK, JJ., Concur.
Opinion subject to revision prior to official publication.
18